RWJBarnabas Health and Rutgers Cancer Institute of New Jersey | Strategic Alliance Partners

As New Jersey’s only National Cancer Institute (NCI) – designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey together with RWJBarnabas Health offers the most advanced cancer treatment options including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex surgical procedures. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy – many of which are not widely available – these cutting-edge therapies are available to adult and pediatric patients. Some of these treatments are fueled by onsite research in which physicians and scientists work side by side to advance our understanding of cancer and transform laboratory discoveries into clinical practice.

Latest from RWJBarnabas Health and Rutgers Cancer Institute of New Jersey


$3.5 Million NIH Grant to Rutgers Cancer Institute of New Jersey Will Support a New ‘Lens’ in Lung Cancer Screening

May 12, 2022

With the aid of a $3.5 million National Institutes of Health grant, investigators from Rutgers Cancer Institute of New Jersey, along with Holden Cancer Center at the University of Iowa, and the University of Texas MD Anderson Cancer Center, are collaborating on a project to address lung cancer screening disparities among individuals with a history of heavy smoking

Examining the Development of T-cell Acute Lymphoblastic Leukemia

December 31, 2021

Despite advances in treatments for T-cell acute lymphoblastic leukemia, patients have an extremely poor prognosis, highlighting the need to explore the genetic components that lead to the formation of the disease, as well as the need to discover new targeted therapeutic approaches and treatment resistance

Hochster Underscores Headway Made in Gastric/GEJ Cancers

December 16, 2021

Dr. Hochster provides insight into the current gastric/GEJ landscape, spotlighting molecular testing approaches, the roles of chemoimmunotherapy combinations, ongoing research with biomarkers of response, and optimal treatment sequencing for patients with HER2-positive disease.

De-Escalated Approaches Continue to Show Benefit in HER2+ Breast Cancer

December 02, 2021

Deborah L. Toppmeyer, MD, discusses clinical trials involving treatments for HER2-positive and triple-negative breast cancer, as well as the importance of making these trials accessible to all patient populations in an attempt to address disparities.

Germline Testing: Exploring How DNA Impacts Cancer Risk and Treatment

December 01, 2021

Researchers from Rutgers Cancer Institute of New Jersey and Dana-Farber Cancer Institute developed and evaluated a computational pipeline that utilizes information commonly provided in tumor sequencing assays to predict the origin of detected DNA alterations.